Edition:
United Kingdom

BioDelivery Sciences International Inc (BDSI.OQ)

BDSI.OQ on NASDAQ Stock Exchange Capital Market

4.36USD
7:55pm BST
Change (% chg)

$0.00 (+0.11%)
Prev Close
$4.36
Open
$4.35
Day's High
$4.45
Day's Low
$4.35
Volume
62,443
Avg. Vol
207,608
52-wk High
$5.36
52-wk Low
$2.40

Latest Key Developments (Source: Significant Developments)

Biopharma Credit Entered Into A Definitive Senior Secured Term Loan Agreement
Wednesday, 29 May 2019 

May 29 (Reuters) - BioDelivery Sciences International Inc ::BIOPHARMA CREDIT PLC - ENTERED INTO A DEFINITIVE SENIOR SECURED TERM LOAN AGREEMENT FOR UP TO US$80 MILLION WITH BIODELIVERY SCIENCES.BIOPHARMA CREDIT - BPCR ACQUIRED 5,000,000 BDSI SHARES AT US$5.00 EACH FOR A TOTAL COST OF US$25 MILLION IN A PUBLIC OFFERING THAT PRICED ON 11 APRIL 2019.BIOPHARMA CREDIT PLC - LOAN WILL MATURE IN MAY 2025 AND BEARS INTEREST AT LIBOR PLUS 7.5%, ALONG WITH 2% ADDITIONAL CONSIDERATION.  Full Article

BioDelivery Sciences Strengthens Financial Position With Debt Refinancing
Tuesday, 28 May 2019 

May 28 (Reuters) - BioDelivery Sciences International Inc ::BIODELIVERY SCIENCES STRENGTHENS FINANCIAL POSITION WITH DEBT REFINANCING.BIODELIVERY SCIENCES INTERNATIONAL INC - NEW AGREEMENT IS CASH FLOW ACCRETIVE, LOWERS COST OF CAPITAL AND EXTENDS DEBT MATURITY.BIODELIVERY SCIENCES INTERNATIONAL INC - REDUCES ANNUAL INTEREST COSTS BY APPROXIMATELY $1.5 MILLION.BIODELIVERY SCIENCES INTERNATIONAL - NEW FACILITY CONSISTS OF A $60.0 MILLION TERM LOAN.BIODELIVERY SCIENCES - PROCEEDS FROM FINANCING, AVAILABLE CASH ON HAND, USED TO REPAY & RETIRE EXISTING TERM LOAN WITH CRG SERVICING LLC.  Full Article

Biodelivery Sciences Q1 Loss Per Share $0.05
Monday, 6 May 2019 

May 6 (Reuters) - BioDelivery Sciences International Inc ::BIODELIVERY SCIENCES REPORTS STRONG FIRST QUARTER 2019 RESULTS AND RAISES BELBUCA® FULL-YEAR EXPECTATIONS.Q1 LOSS PER SHARE $0.05.Q1 REVENUE $19.8 MILLION VERSUS REFINITIV IBES ESTIMATE OF $19.3 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $-0.08 -- REFINITIV IBES DATA.SEES FY 2019 SALES $92 MILLION TO $100 MILLION.RAISES FULL-YEAR BELBUCA NET SALES EXPECTATIONS TO $83 - $88 MILLION.FY2019 REVENUE VIEW $94.6 MILLION -- REFINITIV IBES DATA.REITERATED EXPECTATION TO HAVE POSITIVE CASH FLOW FROM OPERATIONS BY YEAR END.  Full Article

Biodelivery Sciences International Announces Pricing Of Public Offering Of Common Stock
Thursday, 11 Apr 2019 

April 11 (Reuters) - BioDelivery Sciences International Inc ::BIODELIVERY SCIENCES INTERNATIONAL, INC. ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING PRICED AT $5.00PER SHARE.  Full Article

BioDelivery Sciences International Inc Increases Belbuca 2019 Net Sales Expectations To $80 Mln-$85 Mln
Thursday, 14 Mar 2019 

March 14 (Reuters) - BioDelivery Sciences International Inc ::BIODELIVERY SCIENCES INTERNATIONAL INC - INCREASES BELBUCA 2019 NET SALES EXPECTATIONS TO $80-$85 MILLION.BIODELIVERY SCIENCES INTERNATIONAL INC SEES OPERATING CASH FLOW TO BECOME POSITIVE IN 2019.BIODELIVERY SCIENCES INTERNATIONAL INC - LONG-TERM POTENTIAL FOR BELBUCA NET SALES BELIEVED TO BE $250-$300 MILLION.BIODELIVERY SCIENCES INTERNATIONAL - TOTAL NET REVENUE FOR Q4 $18.0 MILLION VERSUS $14.2 MILLION IN Q3 OF 2018.BIODELIVERY SCIENCES INTERNATIONAL INC QTRLY LOSS PER SHARE $0.10.BIODELIVERY SCIENCES INTERNATIONAL INC SEES 2019 TOTAL COMPANY NET REVENUE TO BE IN RANGE OF $85-$90 MILLION.BIODELIVERY SCIENCES INTERNATIONAL - AT DECEMBER 31, 2018, CASH AND CASH EQUIVALENTS OF APPROXIMATELY $43.8 MILLION.  Full Article

Biodelivery Sciences Appoints Terry Coelho As Chief Financial Officer
Tuesday, 15 Jan 2019 

Jan 15 (Reuters) - BioDelivery Sciences International Inc ::BIODELIVERY SCIENCES APPOINTS TERRY COELHO AS CHIEF FINANCIAL OFFICER.BIODELIVERY SCIENCES INTERNATIONAL INC - COELHO SUCCEEDS ERNIE DE PAOLANTONIO WHO IS RETIRING FROM COMPANY AS PREVIOUSLY ANNOUNCED.BIODELIVERY SCIENCES INTERNATIONAL - MOST RECENTLY, COELHO SERVED AS CFO AND TREASURER AT BALCHEM CORP.  Full Article

Biodelivery Sciences International Q3 GAAP Loss Per Share $0.29
Thursday, 8 Nov 2018 

BioDelivery Sciences International Inc ::BIODELIVERY SCIENCES REPORTS STRONG THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 NON-GAAP LOSS PER SHARE $0.10.Q3 GAAP LOSS PER SHARE $0.29.Q3 REVENUE $14.2 MILLION VERSUS I/B/E/S VIEW $13.9 MILLION.Q3 EARNINGS PER SHARE VIEW $-0.14 -- THOMSON REUTERS I/B/E/S.  Full Article

BioDelivery Sciences International Q2 Loss Per Share $0.16
Thursday, 9 Aug 2018 

Aug 9 (Reuters) - BioDelivery Sciences International Inc ::BIODELIVERY SCIENCES REPORTS STRONG SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.16.Q2 REVENUE $12.2 MILLION VERSUS I/B/E/S VIEW $12.3 MILLION.Q2 EARNINGS PER SHARE VIEW $-0.18 -- THOMSON REUTERS I/B/E/S.AT JUNE 30, 2018, CO HAD CASH AND CASH EQUIVALENTS OF APPROXIMATELY $55.7 MILLION.2018 NET REVENUE IS EXPECTED TO BE IN RANGE OF $41 MILLION - $43 MILLION FOR BELBUCA.SEES 2018 TOTAL COMPANY NET REVENUE TO BE IN RANGE OF $50 MILLION - $52 MILLION.  Full Article

BioDelivery Sciences Announces Pricing Of $50 Million Equity Financing
Thursday, 17 May 2018 

May 17 (Reuters) - BioDelivery Sciences International Inc ::BIODELIVERY SCIENCES ANNOUNCES PRICING OF $50 MILLION EQUITY FINANCING.BIODELIVERY SCIENCES INTERNATIONAL INC - SERIES B STOCK IS BEING SOLD FOR $10,000 PER SHARE.BIODELIVERY SCIENCES - EACH SHARE OF SERIES B STOCK WILL BE CONVERTIBLE INTO NUMBER OF SHARES OF COMMON STOCK DETERMINED BY DIVIDING $10,000 BY $1.80.  Full Article

Broadfin Capital Reports 7.3 Pct Stake In Biodelivery Sciences
Tuesday, 10 Apr 2018 

April 10 (Reuters) - BioDelivery Sciences International Inc ::BROADFIN CAPITAL LLC REPORTS 7.3 PCT STAKE IN BIODELIVERY SCIENCES INTERNATIONAL INC AS OF APRIL 5 - SEC FILING .PURCHASED BIODELIVERY SCIENCES INTERNATIONAL SHARES BASED ON BELIEF THAT SHARES, WHEN PURCHASED, "WERE UNDERVALUED".INTEND TO ENGAGE IN DISCUSSIONS WITH BIODELIVERY SCIENCES INTERNATIONAL REGARDING BOARD STRUCTURE AND COMPOSITION.WAS INFORMED BIODELIVERY SCIENCES NOMINATING COMMITTEE DECIDED NOT TO PROCEED WITH APPOINTMENT OF STOCKHOLDER REPRESENTATIVE.IF MUTUALLY AGREEABLE RESOLUTION WITH BIODELIVERY SCIENCES INTERNATIONAL NOT REACHED, RESERVE RIGHTS TO NOMINATE DIRECTOR CANDIDATES.  Full Article